Paramita Therapeutics, Inc. is an early-stage biotech startup based in San Diego, CA, founded in 2018 by Drs. Sang Van and Jack Bui. Specializing in the development of targeted immunotherapies, Paramita utilizes their proprietary water-soluble multivalent conjugation platform technologies to combat cancer and infectious diseases, such as COVID-19.
Despite facing setbacks due to the pandemic, Paramita secured pre-seed funding in 2018 and received a Phase 1 small business innovation research (SBIR) award from the National Science Foundation (NSF) in 2021. With a focus on developing dual-function therapeutic and vaccine products, Paramita aims to complete preclinical and toxicology studies for advanced prostate and ovarian cancer.
Generated from the website